4D Molecular Therapeutics, Inc. (FDMT) Profit Margins
Over the twelve months to 2026-06-30, 4D Molecular Therapeutics, Inc. (FDMT) had operating margin -214.2%, net margin -194.7%, free cash flow margin -169.5%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FDMT4D Molecular Therapeutics, Inc.Follow FDMT — free
—
Price chart with a free account
- Market cap
- 779.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating margin | -424.0% | -395.5% | -3516.5% | -544.6% | -507678.4% | -187.2% | -214.2% | |
| Net margin | -424.3% | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% | -194.7% | |
| FCF margin | -388.5% | -433.8% | -3139.1% | -379.1% | -373975.7% | -128.6% | -169.5% |
USD millions · SEC XBRL
4D Molecular Therapeutics, Inc. — questions
- What is 4D Molecular Therapeutics, Inc.'s operating margin?
- -214.2% over the twelve months to 2026-06-30.
- What is 4D Molecular Therapeutics, Inc.'s net profit margin?
- -194.7% over the twelve months to 2026-06-30.
Every figure on this page comes from 4D Molecular Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.